Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Sep;41(6):520-6.
doi: 10.1002/eat.20541.

Memantine in the treatment of binge eating disorder: an open-label, prospective trial

Brian P Brennan  1 , Jacqueline L Roberts, Kate V Fogarty, Karina A Reynolds, Jeffrey M Jonas, James I Hudson
Affiliations
Clinical Trial

Memantine in the treatment of binge eating disorder: an open-label, prospective trial

Brian P Brennan et al. Int J Eat Disord. 2008 Sep.

Abstract

Objective: To assess preliminarily the efficacy of memantine in binge eating disorder.

Method: This was an open-label, 12-week, flexible-dose (5-20 mg/day) trial of memantine in binge eating disorder. The primary outcome was frequency of binge days. Secondary outcomes included frequency of binge episodes, body-mass index (BMI), weight, Clinical Global Impressions Severity (CGI-S), Three Factor Eating Questionnaire (TFEQ), Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), and Sheehan Disability Scale (SDS). Longitudinal random regression analysis was performed for frequency of binge days and episodes, BMI, weight, and CGI-S; analysis of baseline to endpoint change was performed for all outcomes.

Results: Sixteen individuals received memantine; 15 completed at least one postbaseline evaluation, 9 completed the study. Mean dose at endpoint was 18.3 mg/day. Memantine was associated with significant reductions in frequency of binge days and episodes, severity of illness (p < .001 for both analyses), disinhibition on the TFEQ (p = .015), and disability on the SDS (p < .05 for three subscales). There was no significant change in BMI, weight, MADRS, HAM-A, and TFEQ cognitive restraint and hunger.

Conclusion: In this open-label trial, memantine was well tolerated and effective in reducing binge eating, severity of illness, and disability, but had little effect on BMI and weight.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Hunger, Satiety, and Their Vulnerabilities.
    Stevenson RJ, Boutelle K. Stevenson RJ, et al. Nutrients. 2024 Sep 6;16(17):3013. doi: 10.3390/nu16173013. Nutrients. 2024. PMID: 39275328 Free PMC article. Review.
  • GLP-1-directed NMDA receptor antagonism for obesity treatment.
    Petersen J, Ludwig MQ, Juozaityte V, Ranea-Robles P, Svendsen C, Hwang E, Kristensen AW, Fadahunsi N, Lund J, Breum AW, Mathiesen CV, Sachs L, Moreno-Justicia R, Rohlfs R, Ford JC, Douros JD, Finan B, Portillo B, Grose K, Petersen JE, Trauelsen M, Feuchtinger A, DiMarchi RD, Schwartz TW, Deshmukh AS, Thomsen MB, Kohlmeier KA, Williams KW, Pers TH, Frølund B, Strømgaard K, Klein AB, Clemmensen C. Petersen J, et al. Nature. 2024 May;629(8014):1133-1141. doi: 10.1038/s41586-024-07419-8. Epub 2024 May 15. Nature. 2024. PMID: 38750368 Free PMC article.
  • Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment.
    Fadahunsi N, Petersen J, Metz S, Jakobsen A, Vad Mathiesen C, Silke Buch-Rasmussen A, Kurgan N, Kjærgaard Larsen J, Andersen RC, Topilko T, Svendsen C, Apuschkin M, Skovbjerg G, Hendrik Schmidt J, Houser G, Elgaard Jager S, Bach A, Deshmukh AS, Kilpeläinen TO, Strømgaard K, Madsen KL, Clemmensen C. Fadahunsi N, et al. Sci Adv. 2024 Mar;10(9):eadg2636. doi: 10.1126/sciadv.adg2636. Epub 2024 Mar 1. Sci Adv. 2024. PMID: 38427737 Free PMC article.
  • NMDA Receptors in Accumbal D1 Neurons Influence Chronic Sugar Consumption and Relapse.
    Wei S, Hertle S, Spanagel R, Bilbao A. Wei S, et al. eNeuro. 2021 May 17;8(3):ENEURO.0029-21.2021. doi: 10.1523/ENEURO.0029-21.2021. Print 2021 May-Jun. eNeuro. 2021. PMID: 33906970 Free PMC article.
  • Converging vulnerability factors for compulsive food and drug use.
    Serafine KM, O'Dell LE, Zorrilla EP. Serafine KM, et al. Neuropharmacology. 2021 Sep 15;196:108556. doi: 10.1016/j.neuropharm.2021.108556. Epub 2021 Apr 20. Neuropharmacology. 2021. PMID: 33862029 Free PMC article. Review.
See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources